FDA approves Shionogi’s Xocova as First Oral Post-Exposure Covid-19 Prevention Therapy, marking a major milestone for Covid-19 prevention treatments. FDA has approved Shionogi’s Xocova (ensitrelvir) ...

Ensitrelvir, marketed as Xocova, works by inhibiting viral replication and is designed as a 5-day oral protective regimen, ...

The FDA has approved the oral antiviral Xocova (ensitrelvir) for postexposure prophylaxis of COVID-19 in adults and adolescents.

FDA approves ensitrelvir for COVID-19 postexposure prophylaxis following phase 3 data showing efficacy against Omicron symptoms. The FDA recently approved ensitrelvir (Xocova; Shionogi), an ...

Wastewater signals show BA.3.2 across 25 states, while NWSS funding reductions threaten program continuity after FY2025, diminishing national situational awareness for emerging variants. Genomic ...

Sneezing in the morning, a runny nose or coughing often goes unnoticed as minor ailments in kids. However, these harmless ...

Ugh, in case our allergies weren't bad enough.

A cough that lingers after a cold or the flu is usually not something to worry about. Known as a post-infectious or post-viral cough, this lingering cough affects 11% to 25% of adults who have ...